Previous 10 | Next 10 |
The following slide deck was published by Biohaven Pharmaceutical Holding Company Ltd. in conjunction with their 2021 Q4 earnings call. For further details see: Biohaven Pharmaceutical Holding Company Ltd. 2021 Q4 - Results - Earnings Call Presentation
Gainers: Aerie Pharmaceuticals (NASDAQ:AERI) +25%. Schrodinger (NASDAQ:SDGR) +17%. MDxHealth (NASDAQ:MDXH) +16%. Lantheus (NASDAQ:LNTH) +13%. Tabula Rasa HealthCare (NASDAQ:TRHC) +13%. Losers: Baudax Bio BXRX -55%. The Joint (NASDAQ:JYNT) -15%. Biohaven...
Biohaven Pharmaceutical (NYSE:BHVN) and Pfizer (NYSE:PFE) said a committee of the European Medicines Agency (EMA) recommended the approval of 75 mg dose of rimegepant for the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults...
Biohaven Pharmaceuticals press release (NYSE:BHVN): Q4 Non-GAAP EPS of -$2.32 misses by $0.39. Revenue of $190.01M (+441.2% Y/Y) beats by $14.47M. For further details see: Biohaven Pharmaceuticals Non-GAAP EPS of -$2.32 misses by $0.39, revenue of $190.01M beats by $14.47M
Coinciding with the company’s Q4 2021 results, neurology-focused biotech, Biohaven Pharmaceutical (NYSE:BHVN) announced a licensing deal with Bristol Myers Squibb (NYSE:BMY) and an agreement to acquire Channel Biosciences. The worldwide license agreement with Bristol Myers (BMY) covers...
BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS - NURTEC ODT® (rimegepant) net product revenue was $190.0 million for the fourth quarter of 2021 and $462.5 million for full year 2021 with over 1,600,000 prescriptions fro...
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment PR Newswire NEW HAVEN, Conn. and NEW YORK , Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE) today announced that the C...
Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences - Acquisition of next-generation Kv7 channel activators for target indications including epilepsy, pain disorders a...
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb - Biohaven acquires worldwide rights to phase 3-ready neuromuscular program - Taldefgrobep alfa expands Biohaven's portfolio of innovativ...
Biohaven Pharmaceuticals (NYSE:BHVN) is scheduled to announce Q4 earnings results on Friday, February 25th, before market open. The consensus EPS Estimate is -$1.93 (+28.3% Y/Y) and the consensus Revenue Estimate is $176.93M (+403.9% Y/Y). Over the last 2 years, BHVN has beaten EPS estimates ...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
2024-07-24 06:30:09 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for BHVN on July 24, 2024 04:48AM ET. BHVN was trading at $37.81 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy reco...
2024-07-24 06:00:03 ET Terence Flynn from Morgan Stanley issued a price target of $58.00 for BHVN on 2024-07-24 04:48:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $37.81. The overall price target consensus is at $4...
2024-07-20 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...